André Ulmann

Biography

André Ulmann’s professional career in the healthcare sector spans over 30 years in medical practice, research and the pharmaceutical industry. André’s knowledge of the development of pharmaceutical products and industry expertise is of great benefit as an advisor to Advicenne development. André founded HRA Pharma in 1996 and was the company’s Chief Executive Officer until he assumed the position of Chairman of the Board for the company in April 2009. Under his leadership, HRA Pharma has developed into a socially-committed pharmaceutical company that designs products, devices, and supporting services in niche areas of health, and makes them available to doctors and patients worldwide, reaching €33 million in sales in 2008. In 1999, HRA Pharma launched its first product, NorLevo. Known to the general public worldwide as “the morning-after pill”, NorLevo established HRA Pharma as a pioneer in emergency contraception. Now available in over 50 countries, NorLevo has enabled millions of women worldwide to have greater control over their own reproductive health than ever before. André’s career in healthcare began as a physician and he practiced at the Necker Hospital in Paris, where he was chief resident in Nephrology. André then joined the French company, Roussel-Uclaf, where he worked for over a decade. He began as International Project Leader for the development of RU 486. He was then appointed Medical Director of Laboratoire Roussel France and, following this, served at the helm of four different therapeutic areas within Roussel-Uclaf and Hoechst-Marion-Roussel: international clinical research, endocrinology and immunology, neurobiology, and bone diseases.

Research Interest

clinical research, endocrinology and immunology, neurobiology, and bone diseases